淋巴瘤凝血异常机制及预后评估作用

摘要/Abstract

摘要：

淋巴瘤是最常见的血液系统恶性肿瘤,常伴有凝血系统的异常。凝血系统的异常常导致血栓栓塞及出血等并发症,极大地增加了淋巴瘤患者死亡率。淋巴瘤患者凝血系统异常的机制主要包括肿瘤细胞分泌促凝因子的直接促凝机制及肿瘤细胞激活宿主细胞促凝潜力的间接促凝机制。淋巴瘤患者凝血功能相关因子的改变可能与淋巴瘤预后相关。

柴玥, 董梅. 淋巴瘤凝血异常机制及预后评估作用[J]. 国际肿瘤学杂志, 2020, 47(10): 637-640.

Chai Yue, Dong Mei. Prognostic role and mechanisms of abnormal coagulation system in lymphoma[J]. Journal of International Oncology, 2020, 47(10): 637-640.

参考文献34

[1]	Sanfilippo KM, Wang TF, Gage BF, et al. Incidence of venous thromboembolism in patients with non-Hodgkin lymphoma[J]. Thromb Res, 2016,143:86-90. DOI: 10.1016/j.thromres.2016.05.008. doi:10.1016/j.thromres.2016.05.008pmid:27208462
[2]	Hohaus S, Tisi MC, Bartolomei F, et al. Risk factors for venous thromboembolism in patients with lymphoma requiring hospitalization[J]. Blood Cancer J, 2018,8(6):54. DOI: 10.1038/s41408-018-0096-1. doi:10.1038/s41408-018-0096-1pmid:29884791
[3]	Mooberry MJ, Key NS. Microparticle analysis in disorders of hemostasis and thrombosis[J]. Cytometry A, 2016,89(2):111-122. DOI: 10.1002/cyto.a.22647. doi:10.1002/cyto.a.22647pmid:25704723
[4]	Ball S, Nugent K. Microparticles in hematological malignancies: role in coagulopathy and tumor pathogenesis[J]. Am J Med Sci, 2018,355(3):207-214. DOI: 10.1016/j.amjms.2017.11.014. doi:10.1016/j.amjms.2017.11.014pmid:29549921
[5]	Hisada Y, Mackman N. Tissue factor and cancer: regulation, tumor growth, and metastasis[J]. Semin Thromb Hemost, 2019,45(4):385-395. DOI: 10.1055/s-0039-1687894. doi:10.1055/s-0039-1687894pmid:31096306
[6]	Xia Q, Zhang X, Chen Q, et al. Down-regulation of tissue factor inhibits invasion and metastasis of non-small cell lung cancer[J]. J Cancer, 2020,11(5):1195-1202. DOI: 10.7150/jca.37321. doi:10.7150/jca.37321pmid:31956365
[7]	Han X, Guo B, Li Y, et al. Tissue factor in tumor microenvironment: a systematic review[J]. J Hematol Oncol, 2014,7:54. DOI: 10.1186/s13045-014-0054-8. doi:10.1186/s13045-014-0054-8pmid:25084809
[8]	Chi S, Ikezoe T. Disseminated intravascular coagulation in non-Hodgkin lymphoma[J]. Int J Hematol, 2015,102(4):413-419. DOI: 10.1007/s12185-015-1854-5. doi:10.1007/s12185-015-1854-5pmid:26272605
[9]	Falanga A, Russo L, Milesi V, et al. Mechanisms and risk factors of thrombosis in cancer[J]. Crit Rev Oncol Hematol, 2017,118:79-83. DOI: 10.1016/j.critrevonc.2017.08.003. doi:10.1016/j.critrevonc.2017.08.003pmid:28917273
[10]	Vlodavsky I, Singh P, Boyango I, et al. Heparanase: from basic research to therapeutic applications in cancer and inflammation[J]. Drug Resist Updat, 2016,29:54-75. DOI: 10.1016/j.drup.2016.10.001. doi:10.1016/j.drup.2016.10.001pmid:27912844
[11]	Lupu-Meiri M, Geras-Raaka E, Lupu R, et al. Knock-down of plasminogen-activator inhibitor-1 enhances expression of E-cadherin and promotes epithelial differentiation of human pancreatic adenocarcinoma cells[J]. J Cell Physiol, 2012,227(11):3621-3628. DOI: 10.1002/jcp.24068. doi:10.1002/jcp.24068
[12]	Chen N, Ren M, Li R, et al. Bevacizumab promotes venous thromboembolism through the induction of PAI-1 in a mouse xenograft model of human lung carcinoma[J]. Mol Cancer, 2015,14:140. DOI: 10.1186/s12943-015-0418-x. doi:10.1186/s12943-015-0418-xpmid:26215730
[13]	Reitter EM, Ay C, Kaider A, et al. Interleukin levels and their potential association with venous thromboembolism and survival in cancer patients[J]. Clin Exp Immunol, 2014,177(1):253-260. DOI: 10.1111/cei.12308. doi:10.1111/cei.12308
[14]	Lee EC, Cameron SJ. Cancer and thrombotic risk: the platelet paradigm[J]. Front Cardiovasc Med, 2017,4:67. DOI: 10.3389/fcvm.2017.00067. doi:10.3389/fcvm.2017.00067pmid:29164134
[15]	Grilz E, Marosi C, Königsbrügge O, et al. Association of complete blood count parameters, d-dimer, and soluble P-selectin with risk of arterial thromboembolism in patients with cancer[J]. J Thromb Haemost, 2019,17(8):1335-1344. DOI: 10.1111/jth.14484. doi:10.1111/jth.14484pmid:31099477
[16]	Antonopoulos CN, Sfyroeras GS, Kakisis JD, et al. The role of soluble P selectin in the diagnosis of venous thromboembolism[J]. Thromb Res, 2014,133(1):17-24. DOI: 10.1016/j.thromres.2013.08.014. doi:10.1016/j.thromres.2013.08.014pmid:24012101
[17]	Mauracher LM, Posch F, Martinod K, et al. Citrullinated histone H3, a biomarker of neutrophil extracellular trap formation, predicts the risk of venous thromboembolism in cancer patients[J]. J Thromb Haemost, 2018,16(3):508-518. DOI: 10.1111/jth.13951. doi:10.1111/jth.13951pmid:29325226
[18]	Demers M, Wagner DD. Neutrophil extracellular traps: a new link to cancer-associated thrombosis and potential implications for tumor progression[J]. Oncoimmunology, 2013,2(2):e22946. DOI: 10.4161/onci.22946. doi:10.4161/onci.22946pmid:23526174
[19]	Zhou X, Teegala S, Huen A, et al. Incidence and risk factors of venous thromboembolic events in lymphoma[J]. Am J Med, 2010,123(10):935-941. DOI: 10.1016/j.amjmed.2010.05.021. doi:10.1016/j.amjmed.2010.05.021pmid:20920696
[20]	Abdel-Razeq H, Mansour A, Abdulelah H, et al. Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look![J]. Thromb J, 2018,16:2. DOI: 10.1186/s12959-018-0161-9. doi:10.1186/s12959-018-0161-9pmid:29507532
[21]	Riondino S, Ferroni P, Zanzotto FM, et al. Predicting VTE in cancer patients: candidate biomarkers and risk assessment models[J]. Cancers (Basel), 2019, 11(1). pii: E95. DOI: 10.3390/cancers11010095.
[22]	Mcalister RK, Ito S. Minimal prolongation of prothrombin time with extended exposure to argatroban[J]. Pharmacotherapy, 2015,35(7):e122-e126. DOI: 10.1002/phar.1613. doi:10.1002/phar.1613pmid:26147471
[23]	Fan S, Zhao G, An G. High pretreatment plasma D-dimer levels are associated with shorter overall survival in patients with small cell lung cancer[J]. J Int Med Res, 2019,47(1):215-224. DOI: 10.1177/0300060518799869. doi:10.1177/0300060518799869pmid:30270808
[24]	Malaguarnera M, Latteri S, Bertino G, et al. D-dimer plasmatic levels as a marker for diagnosis and prognosis of hepatocellular carcinoma patients with portal vein thrombosis[J]. Clin Exp Gastroenterol, 2018,11:373-380. DOI: 10.2147/CEG.S172663. doi:10.2147/CEG.S172663pmid:30323642
[25]	Liang Y, He D, Wu L, et al. Elevated preoperative plasma D-dimer dose not adversely affect survival of gastric cancer after gastrectomy with curative intent: a propensity score analysis[J]. Chin J Cancer Res, 2018,30(2):254-262. DOI: 10.21147/j.issn.1000-9604.2018.02.08. doi:10.21147/j.issn.1000-9604.2018.02.08pmid:29861610
[26]	Lee S, Huh SJ, Oh SY, et al. Clinical significance of coagulation factors in operable colorectal cancer[J]. Oncol Lett, 2017,13(6):4669-4674. DOI: 10.3892/ol.2017.6058. doi:10.3892/ol.2017.6058pmid:28599468
[27]	Cao J, Fu Z, Gao L, et al. Evaluation of serum D-dimer, fibrinogen, and CA19-9 for postoperative monitoring and survival prediction in resectable pancreatic carcinoma[J]. World J Surg Oncol, 2017,15(1):48. DOI: 10.1186/s12957-017-1104-9. doi:10.1186/s12957-017-1104-9pmid:28219450
[28]	Feng JF, Yang X, Chen S, et al. Prognostic value of plasma d-dimer in patients with resectable esophageal squamous cell carcinoma in China[J]. J Cancer, 2016,7(12):1663-1667. DOI: 10.7150/jca.15216. doi:10.7150/jca.15216pmid:27698903
[29]	Dirix LY, Salgado R, Weytjens R, et al. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer[J]. Br J Cancer, 2002,86(3):389-395. DOI: 10.1038/sj.bjc.6600069. doi:10.1038/sj.bjc.6600069pmid:11875705
[30]	Liu B, Li B, Zhou P, et al. Prognostic value of pretreatment plasma D-dimer levels in patients with diffuse large B cell lymphoma (DLBCL)[J]. Clin Chim Acta, 2018,482:191-198. DOI: 10.1016/j.cca.2018.04.013. doi:10.1016/j.cca.2018.04.013pmid:29649456
[31]	Lekovic D, Miljic P, Mihaljevic B. Increased risk of venous thromboembolism in patients with primary mediastinal large B-cell lymphoma[J]. Thromb Res, 2010,126(6):477-480. DOI: 10.1016/j.thromres.2010.08.017. doi:10.1016/j.thromres.2010.08.017pmid:21126629
[32]	Diao D, Cheng Y, Song Y, et al. D-dimer is an essential accompaniment of circulating tumor cells in gastric cancer[J]. BMC Cancer, 2017,17(1):56. DOI: 10.1186/s12885-016-3043-1. doi:10.1186/s12885-016-3043-1pmid:28086824
[33]	Berger MD, Heini AD, Seipel K, et al. Increased fibrinogen levels at diagnosis are associated with adverse outcome in patients with acute myeloid leukemia[J]. Hematol Oncol, 2017,35(4):789-796. DOI: 10.1002/hon.2307. doi:10.1002/hon.2307pmid:27301773
[34]	Elmoamly S, Afif A. Can biomarkers of coagulation, platelet activation, and inflammation predict mortality in patients with hematological malignancies?[J]. Hematology, 2018,23(2):89-95. DOI: 10.1080/10245332.2017.1365458. doi:10.1080/10245332.2017.1365458pmid:28823228

淋巴瘤凝血异常机制及预后评估作用

Prognostic role and mechanisms of abnormal coagulation system in lymphoma

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献34

相关文章15

编辑推荐

Metrics

本文评价

[1]	钱晓涛, 石子宜, 胡格, 吴晓维.Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华.炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[4]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[5]	张洁, 范玲, 李杰, 温华, 苏媛媛, 路宁, 张明鑫.原发性胰腺淋巴瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 316-320.
[6]	刘萍萍, 何学芳, 张翼, 杨旭, 张珊珊, 季一飞.原发性脑胶质瘤患者术后复发危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2024, 51(4): 193-197.
[7]	万芳, 杨钢, 李睿, 万启晶.食管癌患者血清miR-497、miR-383水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(4): 204-209.
[8]	姚益新, 沈煜霖.血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[9]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好.基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[10]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹.胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[11]	彭琴, 蔡玉婷, 王伟.KPNA2在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 181-185.
[12]	陈波光, 王苏贵, 张永杰.血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[13]	金旭东, 陈忠坚, 毛伟敏.MTAP基因在恶性间皮瘤中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 99-104.
[14]	黄镇, 陈永顺.循环肿瘤DNA在肝细胞癌诊疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(1): 59-64.
[15]	王潇, 李盈, 罗玉杰, 晋舒.基于列线图模型探讨血清学指标对鼻咽癌预后的判断价值[J]. 国际肿瘤学杂志, 2023, 50(8): 463-469.